30 April 2021 : Clinical Research
Comparison of Different Hydration Strategies in Patients with Very Low-Risk Profiles of Contrast-Induced Nephropathy
Shuai Miao1BCE, Zheng-Kai Xue1B, Ya-Ru Zhang1F, Hao Zhang1A, Jing-Jin Che1C, Tong Liu1DF, Hua-Yue Tao2C, Guangping Li1AD, Kang-Yin Chen1ADG*DOI: 10.12659/MSM.929115
Med Sci Monit 2021; 27:e929115
Table 1 Baseline characteristics of the 3 groups.
| Variables | Preventive group | Remedial group | NH group | P value |
|---|---|---|---|---|
| Age, years | 63.22±7.15 | 62.47±7.44 | 62.85±7.29 | 0.88 |
| Male gender, n (%) | 29 (59.18) | 21 (44.68) | 25 (52.08) | 0.36 |
| Height, cm | 166.31±15.60 | 165.94±7.94 | 166.42±5.67 | 0.97 |
| Weight, Kg | 70.84±11.34 | 68.67±11.51 | 70.33±9.42 | 0.59 |
| BMI, Kg/m | 24.90±2.84 | 24.87±3.21 | 25.33±2.56 | 0.68 |
| Systolic BP, mmHg | 133.45±16.32 | 132.66±16.40 | 137.35±13.26 | 0.28 |
| Diastolic BP, mmHg | 79.00±11.01 | 77.94±10.77 | 77.88±8.83 | 0.83 |
| HR, bpm | 68.92±9.96 | 70.81±9.89 | 69.33±8.75 | 0.59 |
| CAG, n (%) | 25 (51.02) | 26 (55.32) | 26 (54.17) | 0.91 |
| Contrast volume, ml | 89.69±41.66 | 86.81±38.67 | 86.87±40.33 | 0.92 |
| Hypertension, n (%) | 35 (71.43) | 27 (57.45) | 31 (64.58) | 0.36 |
| Stroke, n (%) | 3 (6.12) | 4 (8.51) | 1 (2.08) | 0.38 |
| Cigarette, n (%) | 20 (40.82) | 13 (27.66) | 13 (27.08) | 0.26 |
| Alcohol, n (%) | 6 (12.24) | 6 (12.77) | 6 (12.50) | 0.99 |
| LA, mm | 37.94±4.64 | 36.29±3.99 | 36.56±4.49 | 0.16 |
| LV-d, mm | 47.59±5.63 | 45.97±4.78 | 47.18±3.65 | 0.25 |
| EF, % | 61.59±5.02 | 64.69±4.31 | 63.95±9.38 | 0.07 |
| IVS, mm | 9.59±1.53 | 8.89±1.21 | 9.22±2.06 | 0.13 |
| Aspirin, n (%) | 48 (97.96) | 44 (93.62) | 46 (95.83) | 0.79 |
| Clopidogrel, n (%) | 43 (87.76) | 42 (89.36) | 43 (89.58) | 0.85 |
| β-block, n (%) | 29 (59.18) | 26 (55.32) | 31 (64.58) | 0.72 |
| CCB, n (%) | 20 (40.82) | 19 (40.43) | 16 (33.33) | 0.67 |
| ACEI/ARB, n (%) | 25 (51.02) | 17 (36.17) | 21 (43.75) | 0.39 |
| Statins, n (%) | 42 (85.71) | 39 (82.98) | 40 (83.33) | 0.95 |
| Nitrate, n (%) | 28 (57.14) | 25 (53.19) | 30 (62.50) | 0.72 |
| Hb, g/L | 141.55±12.43 | 137.54±14.49 | 139.69±13.52 | 0.35 |
| HCT, % | 41.08±6.54 | 40.60±3.92 | 41.22±3.60 | 0.81 |
| ALB, g/L | 43.15±2.92 | 42.30±3.03 | 43.02±3.13 | 0.34 |
| TG, mmol/L | 1.40±0.61 | 1.54±0.77 | 1.68±1.33 | 0.36 |
| TC, mmol/L | 4.29±0.96 | 4.62±1.00 | 4.66±1.11 | 0.16 |
| LDL-C, mmol/L | 2.67±0.83 | 2.82±0.75 | 2.88±0.96 | 0.46 |
| Glu, mmol/L | 5.33±0.67 | 5.30±0.53 | 5.42±0.67 | 0.65 |
| eGFR, mL/min/1.73 m | 87.02±21.49 | 92.93±24.64 | 92.43±22.91 | 0.38 |
| V/CrCl | 0.99±0.55 | 0.87±0.41 | 1.00±0.55 | 0.39 |
| HR – heart rate; CAG – coronary arteriography; BMI – body mass index; LA – left atrial diameter; LV-d – left ventricular end diastolic diameter; EF – ejection fraction; IVS – interventricular septal; CCB – calcium channel blocker; ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blockers; Hb – hemoglobin; HCT – hematocrit; ALB – albumin; TG – total triglyceride; TC – total cholesterol; LDL-C – low density lipoprotein cholesterol; Glu – glucose; eGFR – estimated glomerular filtration rate; V/CrCl – ratio of contrast volume-to-creatinine clearance. | ||||